Get the Stockscreener App
0.00
100.00%
-1.71
Aptose Biosciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
See More
Previous Close:
$1.71
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$10.59M
Revenue:
-
Net Income/Loss:
$-35.80M
P/E Ratio:
0.00
EPS:
-2.97
Net Cash Flow:
$-37.18M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$14.28
Aptose Biosciences Inc Stock (APTO) Company Profile
Name
Aptose Biosciences Inc
Sector
Industry
Phone
310-849-8060
Address
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Compare APTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.00 | 10.59M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Feb-20-20 | Initiated | Maxim Group | Buy |
| Feb-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | Piper Sandler | Overweight |
| Mar-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Nov-16-18 | Initiated | B. Riley FBR | Buy |
| Dec-13-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-07-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-08-17 | Initiated | Rodman & Renshaw | Neutral |
View All
Aptose Biosciences Inc Stock (APTO) Latest News
Aptose Biosciences Reports Positive Early Data from TUSCANY Trial for AML Treatment - TipRanks
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial - Yahoo Finance
Aptose Biosciences Advances Tuspetinib in AML Treatment with Promising Trial Results - MSN
Aptose Biosciences: Q2 Earnings Snapshot - Greenwich Time
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports Second Quarter 2025 Results - The Manila Times
When (APS) Moves Investors should Listen (APS:CA) - news.stocktradersdaily.com
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy - The Manila Times
Aptose Biosciences Advances TUSCANY Trial with Dose Escalation - TipRanks
Aptose Cancer Drug Tuspetinib Advances to 160mg Dose After Successful Trial Results | APTOF Stock News - Stock Titan
(APS) Financial Trading Report (APS:CA) - news.stocktradersdaily.com
Where are the Opportunities in (APS) (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Appoints Ernst & Young as New Auditor - The Globe and Mail
Aptose Selects Ernst & Young Global Limited as its New Independe - GuruFocus
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders - The Manila Times
(APS) Equity Trading Insights (APS:CA) - news.stocktradersdaily.com
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML - The Manila Times
About Us - FinancialContent
(APS) Comprehensive Trading Strategy Report (APS:CA) - news.stocktradersdaily.com
Delisting of Securities from The Nasdaq Stock Market - The Globe and Mail
(APS) Technical Patterns and Signals (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Upgrades to OTCQB Market Listing - TipRanks
Aptose Announces Deferral of Interest Payment | APTOF Stock News - GuruFocus
Aptose Announces Deferral of Interest Payment - Yahoo Finance
Aptose Biosciences Secures $8.5M Loan Agreement - TipRanks
(APS) Investment Performance Report (APS:CA) - news.stocktradersdaily.com
(APS) Equity Market Report (APS:CA) - news.stocktradersdaily.com
Precision Biosciences shares fall 1.43% intraday as Aptose Biosciences secures US$8.5 million loan for AML treatment development. - AInvest
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Provides Corporate Updates - The Manila Times
Aptose Provides Corporate Updates | APTOF Stock News - GuruFocus
Aptose CEO props up biotech's finances to prevent company from going bust - Fierce Biotech
(APS) Investment Analysis and Advice (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML - MSN
Aptose Presents Safety, Response, and MRD Clinical Data from TUS - GuruFocus
Aptose reports promising data from TUS+VEN+AZA therapy for AML By Investing.com - Investing.com South Africa
Aptose reports promising data from TUS+VEN+AZA therapy for AML - Investing.com Canada
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - The Manila Times
APTOAptose Announces Reverse Share Split - Revista ADVFN
(APS) Technical Pivots with Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose's Closing of US$3M Investment by Hanmi Pharmaceutical - McCarthy Tétrault LLP
Aptose Biosciences completes Public Offering of Common Shares for US$74.2M - McCarthy Tétrault
Aptose Biosciences Inc. enters into exclusive license agreement with Hanmi Pharmaceutical - McCarthy Tétrault LLP
Aptose Biosciences Inc. Completes US$4.43M Registered Direct Offering and Concurrent Private Placement - McCarthy Tétrault LLP
Aptose Biosciences Inc. announces it entered into a $25M Committed Equity Facility - McCarthy Tétrault
Aptose Biosciences Inc. enters into at-the-market sales agreement with Cantor Fitzgerald & Co. - McCarthy Tetrault
Aptose Biosciences Inc Stock (APTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):